Welcome to our dedicated page for Xilio Therapeutics news (Ticker: XLO), a resource for investors and traders seeking the latest updates and insights on Xilio Therapeutics stock.
Xilio Therapeutics, Inc. develops masked immuno-oncology therapies for people living with cancer. Company news centers on its proprietary masking technology, which is designed to localize anti-tumor activity within the tumor microenvironment, and on pipeline updates for masked biologics and multi-specific I-O molecules.
Recurring developments include preclinical data for programs such as XTX601, a masked T cell engager targeting CLDN18.2, updates on XTX501, a bispecific PD-1 / masked IL-2 program, and disclosures involving masked T cell engager programs targeting PSMA and STEAP1. News also covers financial results, scientific conference presentations, inducement equity grants, board composition, and capital-structure actions.
Xilio Therapeutics (Nasdaq: XLO), a clinical-stage biotechnology company focused on developing tumor-activated immuno-oncology therapies, has announced its participation in the Morgan Stanley 22nd Annual Global Healthcare Conference. The company's president and CEO, René Russo, Pharm.D., will engage in a fireside chat on September 4, 2024, at 7:00 am EDT.
Investors and interested parties can access a live webcast of the presentation through the 'Events & Presentations' section of Xilio's website. The webcast will remain available for 30 days following the event, providing an opportunity for those unable to attend live to catch up on the company's latest developments and strategies in the field of cancer treatment.
Xilio Therapeutics (Nasdaq: XLO) reported Q2 2024 financial results and pipeline updates. Key highlights include:
1. Initiated Phase 2 trial of XTX101 with atezolizumab in MSS CRC patients.
2. Started Phase 1B monotherapy dose expansion for XTX301 in advanced solid tumors.
3. Expects to report clinical data for XTX101 and XTX301 in Q4 2024.
4. Q2 2024 ended with $74.9 million in cash, anticipating runway into Q2 2025.
5. Q2 2024 financial results: $2.4 million license revenue, $11.2 million R&D expenses, $5.8 million G&A expenses, $13.9 million net loss.
6. Promoted Chris Frankenfield to CFO while retaining COO role.
7. Advancing research-stage tumor-activated bispecifics and immune cell engagers.
Xilio Therapeutics, a clinical-stage biotechnology firm, has announced the appointment of Dr. Aoife Brennan and Dr. James Shannon to its board of directors as of June 13, 2024.
Dr. Brennan brings over 16 years of industry leadership, having held executive roles at Synlogic and Biogen, while Dr. Shannon has over 30 years of experience, previously serving as chief medical officer at GlaxoSmithKline and holding leadership positions at Novartis.
Their extensive expertise is expected to significantly contribute to Xilio's ongoing development of novel, tumor-activated immuno-oncology therapies, with several clinical milestones anticipated in the near term.
Xilio Therapeutics (NASDAQ: XLO) announced significant pipeline and business updates alongside its Q1 2024 financial results. Highlighting their progress, they plan to initiate a Phase 2 trial for XTX101, an Fc-enhanced anti-CTLA-4, in combination with atezolizumab for MSS CRC in Q3 2024, and report clinical data in Q4 2024. The XTX301 IL-12 program, partnered with Gilead Sciences, received $43.5M upfront and is set for Phase 1 data release in Q4 2024. Furthermore, Xilio's research efforts on bispecifics and immune cell engagers are advancing. Financially, Xilio ended Q1 2024 with $34M in cash, supplemented by an additional $44.6M from Gilead agreements and private placements, projecting a cash runway until Q2 2025.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.